Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
- Cancer cannot take away John Andretti’s legacyon February 2, 2020 at 3:33 pm
“Cancer is so limited … it cannot cripple love … shatter hope … corrode faith … eat away peace … destroy confidence … kill friendship … shut out memories … silence courage … reduce eternal life … ...
- Tulane, LSU researchers say earlier screenings could help detect colorectal canceron January 31, 2020 at 2:20 pm
Colorectal cancer has typically been a disease associated with aging. And in years past, medical groups did not recommend screening for the disease until age 50. But the reason colon cancer isn’t as ...
- More Fuel for the Colon Cancer Screening Age Debateon January 31, 2020 at 1:34 pm
Analysis of colorectal cancer (CRC) incidence by age in the U.S. revealed a spike right when screening is recommended to begin, indicating that many latent tumors go undiagnosed ahead of routine ...
- Earlier screening for colon cancer may catch cases earlieron January 31, 2020 at 8:47 am
The analysis of colon and rectal cancer rates among adults in the United States found there is a 46 percent increase in new diagnoses from ages 49 to 50, an indication that latent cases are perhaps ...
- Spike in colorectal cancer from age 49 to 50 suggests many undiagnosed before screeningson January 31, 2020 at 8:04 am
A year-by-year age analysis of colorectal cancer rates among U.S. adults finds a 46% increase in new diagnoses from ages 49 to 50, indicating that many latent cases of the disease are likely going ...
- Novel nano-vehicle for delivery and efficiency of anticancer auraptene against colon cancer cellson January 31, 2020 at 2:23 am
The aim of this study is to devise, prepare and characterize nano encapsulated auraptene (AUR) and evaluate cytotoxic and apoptotic effects on HT-29 colon cancer cells. Herein, AUR nano formulations ...
- John Andretti, NASCAR Driver, Dead at 56 Following Colon Cancer Battleon January 30, 2020 at 5:13 pm
The NASCAR and IndyCar driver has died after a battle with colon cancer, Andretti Autosport announced on Thursday. He was 56. “It [is] with the heaviest of hearts we share that John Andretti has ...
- Professional race car driver John Andretti dies at 56 after a long battle with colon canceron January 30, 2020 at 4:06 pm
NASCAR, IndyCar and sports-car racing competitor John Andretti died on Thursday at the age of 56 after a long battle with colon cancer. The Andretti Autosport team confirmed the news. His family ...
- John Andretti, NASCAR driver and nephew of Mario Andretti, dies from colon canceron January 30, 2020 at 1:34 pm
NASCAR driver John Andretti, a nephew of racing legend Mario Andretti, has died from colon cancer, according to a tweet from Andretti Autosport.
- Former NASCAR driver John Andretti dies after long battle with colon canceron January 30, 2020 at 1:18 pm
John Andretti, former IndyCar and NASCAR driver, died on Thursday at age 56 after a long and public battle with colon cancer. Andretti Autosport announced his death on social media. Statement on the ...
via Google News and Bing News